I disagree a bit here when it comes to CHM and IMU as I think both are more and more moving into each other's space. PH confirmed that CF33 is not limited to expressing CD19, a CD17 application and what you suggested MMP2, maybe could work as well.
The other thing is that Hopper runs the 3/4 in the exact same way and that's where my concern comes from. The latest CRs at IMU and RAD came to mind, both a combo of results / licence and CR.
Let's hope for great results only and a fantastic market reaction. Expecting the worst but hoping for the best - my current attitude.
GLTA
CHM Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
(20min delay)